Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
J Int Assoc Physicians AIDS Care (Chic)
; 11(3): 192-7, 2012.
Article
en En
| MEDLINE
| ID: mdl-22247337
ABSTRACT
OBJECTIVE:
To compare the immunologic effectiveness of raltegravir-maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M-) in treatment-experienced patients in clinical practice.METHODS:
We conducted a retrospective study of treatment-experienced HIV-infected adults receiving either R+M+- or R+M--based therapy. Longitudinal CD4 counts were analyzed using a linear mixed model.RESULTS:
One hundred and fifty-six patients were included in the analysis, of whom 32 were receiving R+M+ and 124 R+M-. Mean baseline CD4 counts in patients on R+M+ and R+M- were 463.8 and 442.3 cells/mm(3), respectively (P = .67). In multivariable mixed models, a baseline viral load ≥50 copies/mL was significantly associated with CD4 change during follow-up (P < .0001). No difference between R+M+ and R+M- was observed during follow-up (P = .81).CONCLUSION:
CD4 cell recovery was similar among patients receiving either R+M+- or R+M--based therapy during a 24-month period of follow-up.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Pirrolidinonas
/
Triazoles
/
Infecciones por VIH
/
Fármacos Anti-VIH
/
Ciclohexanos
/
Terapia Antirretroviral Altamente Activa
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Int Assoc Physicians AIDS Care (Chic)
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2012
Tipo del documento:
Article
País de afiliación:
Canadá